Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
暂无分享,去创建一个
Angelo Balestrieri | R. Purcell | P. Farci | A. Balestrieri | H. Alter | Alessandra Coiana | Robert H Purcell | G. Diaz | Patrizia Farci | Luchino Chessa | Harvey J Alter | Rita Strazzera | Stefania Farci | Daniela Degioannis | Giovanna Peddis | Francesco Usai | Giancarlo Serra | Giacomo Diaz | L. Chessa | G. Serra | G. Peddis | A. Coiana | S. Farci | R. Strazzera | Francesco Usai | D. Degioannis
[1] J. Pawlotsky,et al. Evolution of the Hepatitis C Virus Second Envelope Protein Hypervariable Region in Chronically Infected Patients Receiving Alpha Interferon Therapy , 1999, Journal of Virology.
[2] S. Kwok,et al. Avoiding false positives with PCR , 1989, Nature.
[3] S. Mishiro,et al. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients , 1992, Hepatology.
[4] B. Rehermann. Interaction between the Hepatitis C Virus and the Immune System , 2000, Seminars in liver disease.
[5] R. Chung,et al. Mutations in the NS5A region do not predict interferon‐responsiveness in American patients infected with genotype 1b hepatitis C virus , 1999, Journal of medical virology.
[6] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[7] C. Bréchot,et al. Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C , 1997, Hepatology.
[8] B. Korber,et al. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease , 1997, Journal of virology.
[9] C. Pasquier,et al. Genetic Heterogeneity of Hypervariable Region 1 of the Hepatitis C Virus (HCV) Genome and Sensitivity of HCV to Alpha Interferon Therapy , 2000, Journal of Virology.
[10] J. Pawlotsky. Hepatitis C virus resistance to antiviral therapy , 2000, Hepatology.
[11] B. Kronenberger,et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response , 2000 .
[12] P. Klenerman,et al. Viral escape and the failure of cellular immune responses. , 2000, Science.
[13] N. Ogata,et al. Lack of protective immunity against reinfection with hepatitis C virus , 1992 .
[14] K. Chayama,et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection , 1997, Hepatology.
[15] T. Berg,et al. Mutations in the E2‐PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment , 2000, Hepatology.
[16] S. Zeuzem,et al. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa , 1997, Hepatology.
[17] K. Abid,et al. Hepatitis C Virus, the E2 Envelope Protein, and α-Interferon Resistance , 2000 .
[18] S. Ray,et al. Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy , 2000, Journal of Virology.
[19] Hoofnagle Jh. Therapy of acute and chronic viral hepatitis. , 1994 .
[20] N. Hayashi,et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients , 1994, Hepatology.
[21] M. Shapiro,et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Purcell,et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. , 1996, Virology.
[23] R. Purcell,et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. , 1991, The New England journal of medicine.
[24] H. Fusamoto,et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. , 1995, Gastroenterology.
[25] G. Davis,et al. Factors predictive of a beneficial response to therapy of hepatitis C , 1997, Hepatology.
[26] M. Nei,et al. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. , 1986, Molecular biology and evolution.
[27] R H Purcell,et al. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[28] G. Davis,et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C , 1996, Journal of medical virology.
[29] K. Chayama,et al. Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy , 2000, Hepatology.
[30] N. Enomoto,et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment , 1995, Hepatology.
[31] H J Alter,et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.
[32] L. Stuyver,et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. , 1997, Journal of hepatology.
[33] C. Bréchot,et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. , 1997, Gastroenterology.
[34] G. Learn,et al. Maintaining the integrity of human immunodeficiency virus sequence databases , 1996, Journal of virology.
[35] Michael P. Cummings,et al. MEGA (Molecular Evolutionary Genetics Analysis) , 2004 .
[36] Giorgio,et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[37] H J Alter,et al. Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.
[38] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[39] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[40] N Enomoto,et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.
[41] S. Polyak,et al. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b , 1997, Journal of medical virology.
[42] N. Enomoto,et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.
[43] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[44] H. Toyoda,et al. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. , 1997, Journal of hepatology.
[45] D. R. Taylor,et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.
[46] M. Katze,et al. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. , 2001, Virology.
[47] A. Weiner,et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.
[48] M. Houghton. Strategies and prospects for vaccination against the hepatitis C viruses. , 2000, Current topics in microbiology and immunology.
[49] R H Purcell,et al. Clinical significance of hepatitis C virus genotypes and quasispecies. , 2000, Seminars in liver disease.
[50] Deborah R. Taylor. Hepatitis C virus and interferon resistance: It's more than just PKR , 2001, Hepatology.
[51] Richard W. Hamming,et al. Coding and Information Theory , 1980 .